Latest & greatest articles for obesity

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on obesity or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on obesity and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for obesity

1. Treatment options for morbid obesity

. The World Health Organization defines morbid obesity as a body mass index ≥ 40 kg/m 2 or ≥ 35 kg/m 2 in patients with overweight-related comorbidity. Treatment options for morbid obesity include lifestyle interventions alone or in combination with motivational stays, surgical treatments and pharmacological treatments. We found low to moderate quality evidence indicating that, compared to lifestyle interventions alone: Lifestyle interventions with Roux-en-Y gastric bypass probably improve weight loss (...) Treatment options for morbid obesity Treatment options for morbid obesity - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Treatment options for morbid obesity Subscribe me! You have subscribed to alerts about: Treatment options for morbid obesity Oops, something went wrong... ... contact nettredaksjon@fhi.no. ... reload the page and try

2021 Norwegian Institute of Public Health

2. A balancing act: GLP-1 receptor agonists for non-diabetic obesity

Association’s recognition of obesity as a disease in 2013, signal a trend towards a more nuanced understanding of the multifactorial nature of the disease, reducing blame and stigmatization and opening doors for greater investment in therapy, including new medications like GLP-1 agonists. 7 GLP-1 agonists are a promising drug class originally developed for the treatment of type 2 diabetes, but recently shown to be effective for weight loss in non-diabetic patients with obesity or overweight BMI when given (...) intervention significantly improved weight maintenance at 56 weeks when compared with controls (who received placebo and lifestyle intervention) in overweight and obese individuals who had already lost at least 5% of initial body weight during a low-calorie diet prior to randomization. 13 Semaglutide, another GLP-1 agonist already approved for type 2 diabetes treatment, is also in ongoing trials for obesity treatment in patients without diabetes 14 and may provide a greater weight loss benefit than

2021 Clinical Correlations

3. Setmelanotide (Imcivree) - To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency

Setmelanotide (Imcivree) - To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency Drug Approval Package: IMCIVREE U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IMCIVREE Company: Rhythm Pharmaceuticals Inc. Application Number: 213793 Approval Date: 11/25/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF

2021 FDA - Drug Approval Package

4. Liraglutide for managing overweight and obesity

Liraglutide for managing overweight and obesity Liraglutide for managing overweight and obesity T echnology appraisal guidance Published: 9 December 2020 www.nice.org.uk/guidance/ta664 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Liraglutide for managing overweight and obesity (TA664) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 18Contents Contents 1 Recommendations 4 2 Information about liraglutide 6 Marketing authorisation 6 Dosage in the marketing authorisation 6 Price 6 3 Committee discussion 7

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

5. Whole systems approach to obesity

Whole systems approach to obesity Whole systems approach to obesity - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Whole systems approach to obesity A guide and set of resources to support local authorities with implementing a whole systems approach to address obesity and promote a healthy weight. Published 25 July 2019 From: Documents Ref: PHE publications gateway number GW-534 If you use assistive (...) This guide and set of resources can be used to support the implementation of a whole systems approach to obesity. It is intended for local authorities and partners, including the NHS, local businesses and the community and voluntary sector. The guide covers: the role of local authorities the benefits of taking a whole systems approach the 6-phase process - each phase provides practical support Each phase has accompanying . Included with the guide is a separate ‘learning report’, explaining the findings

2020 Public Health England

6. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study

Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Nov 9;dc200358. doi: 10.2337/dc20-0358. Online ahead of print. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Centers for Disease Control and Prevention, Atlanta

2020 EvidenceUpdates

7. A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT Full Text available with Trip Pro

A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2020 NIHR HTA programme

8. Fit and Strong! Plus: Twelve and eighteen month follow-up results for a comparative effectiveness trial among overweight/obese older adults with osteoarthritis Full Text available with Trip Pro

Fit and Strong! Plus: Twelve and eighteen month follow-up results for a comparative effectiveness trial among overweight/obese older adults with osteoarthritis Fit and Strong! Plus: Twelve and eighteen month follow-up results for a comparative effectiveness trial among overweight/obese older adults with osteoarthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) . 2020 Oct 3;141:106267. doi: 10.1016/j.ypmed.2020.106267. Online ahead of print. Fit and Strong! Plus: Twelve and eighteen month follow-up results for a comparative effectiveness trial among overweight/obese older adults with osteoarthritis , , , , , , , Affiliations Expand Affiliations 1 Institute for Health Research and Policy, School of Public Health, University of Illinois at Chicago, 1747 West Roosevelt Road, Chicago, IL 60608, United States of America; University of Illinois Cancer Center, 818

2020 EvidenceUpdates

9. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial Full Text available with Trip Pro

Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Actions . 2020 Sep 28;180(11):1-9. doi: 10.1001/jamainternmed.2020.4153. Online ahead of print. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial , , , , , , , , , , , Affiliations Expand Affiliations 1 Cardiovascular Research Institute, University of California, San Francisco, San Francisco. 2 Cardiology Division, University of California, San Francisco, San Francisco. 3 Center

2020 EvidenceUpdates

10. Management of Adult Overweight and Obesity

Management of Adult Overweight and Obesity VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF ADULT OVERWEIGHT AND OBESITY Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision making. They are not intended to define a standard of care and should (...) and/or therapeutic interventions within these guidelines does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor. Version 3.0 – 2020VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity July 2020 Page 2 of 147 Prepared by: The Management of Adult Overweight and Obesity Work Group With support from: The Office of Quality and Patient

2020 VA/DoD Clinical Practice Guidelines

11. Effect of Prophylactic Negative Pressure Wound Therapy vs Standard Wound Dressing on Surgical-Site Infection in Obese Women After Cesarean Delivery: A Randomized Clinical Trial. (Abstract)

Effect of Prophylactic Negative Pressure Wound Therapy vs Standard Wound Dressing on Surgical-Site Infection in Obese Women After Cesarean Delivery: A Randomized Clinical Trial. Obesity increases the risk of both cesarean delivery and surgical-site infection. Despite widespread use, it is unclear whether prophylactic negative pressure wound therapy reduces surgical-site infection after cesarean delivery in obese women.To evaluate whether prophylactic negative pressure wound therapy, initiated (...) immediately after cesarean delivery, lowers the risk of surgical-site infections compared with standard wound dressing in obese women.Multicenter randomized trial conducted from February 8, 2017, through November 13, 2019, at 4 academic and 2 community hospitals across the United States. Obese women undergoing planned or unplanned cesarean delivery were eligible. The study was terminated after 1624 of 2850 participants were recruited when a planned interim analysis showed increased adverse events

2020 JAMA

12. Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes. Full Text available with Trip Pro

Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes. Overweight and obesity are increasing worldwide and are considered to be a major public health issue of the 21st century. Introducing taxation of the fat content in foods is considered a potentially powerful policy tool to reduce consumption of foods high in fat or saturated fat, or both.To assess the effects of taxation of the fat content in food on consumption of total (...) fat and saturated fat, energy intake, overweight, obesity, and other adverse health outcomes in the general population.We searched CENTRAL, Cochrane Database of Systematic Reviews, MEDLINE, Embase, and 15 other databases and trial registers on 12 September 2019. We handsearched the reference lists of all records of included studies, searched websites of international organizations and institutions (14 October 2019), and contacted review advisory group members to identify planned, ongoing

2020 Cochrane

13. Effect of alternate-day fasting on obesity and cardiometabolic risk: A systematic review and meta-analysis

with obesity. However, there was no difference between ADF and continuous energy restriction, time-restricted feeding, or control with regard to lean body mass. Conclusions: Current evidence suggests that ADF effectively lowers BMI, BW, FM, and total cholesterol in adults with overweight within 6 months compared to the control. Keywords: Alternate-day fasting; Body fat mass; Body mass index; Cardiometabolic risk; Intermittent fasting; Obesity. Copyright © 2020 Elsevier Inc. All rights reserved. Conflict (...) Effect of alternate-day fasting on obesity and cardiometabolic risk: A systematic review and meta-analysis Effect of alternate-day fasting on obesity and cardiometabolic risk: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest

2020 EvidenceUpdates

14. Text messaging and financial incentives to encourage weight loss in men with obesity: the Game of Stones feasibility RCT Full Text available with Trip Pro

Text messaging and financial incentives to encourage weight loss in men with obesity: the Game of Stones feasibility RCT Text messaging and financial incentives to encourage weight loss in men with obesity: the Game of Stones feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above

2020 NIHR HTA programme

15. Obesity, weight management and people with learning disabilities

Obesity, weight management and people with learning disabilities Obesity, weight management and people with learning disabilities - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance and support Guidance Obesity, weight management and people with learning disabilities Guidance

2020 Public Health England

16. Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial. (Abstract)

Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial. Midterm effects of bariatric surgery on patients with obesity and hypertension remain uncertain.To determine the 3-year effects of Roux-en-Y gastric bypass (RYGB) on blood pressure (BP) compared with medical therapy (MT) alone.Randomized clinical trial. (ClinicalTrials.gov: NCT01784848).Investigator-initiated study at Heart Hospital (HCor), São Paulo, Brazil.Patients

2020 Annals of Internal Medicine

17. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Full Text available with Trip Pro

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Obesity, race/ethnicity, and other correlated characteristics have emerged as high-profile risk factors for adverse coronavirus disease 2019 (COVID-19)-associated outcomes, yet studies have not adequately disentangled their effects.To determine the adjusted effect of body mass index (BMI), associated comorbidities, time, neighborhood-level sociodemographic factors, and other (...) for death, even after adjustment for obesity-related comorbidities. Compared with patients with a BMI of 18.5 to 24 kg/m2, those with BMIs of 40 to 44 kg/m2 and greater than 45 kg/m2 had relative risks of 2.68 (95% CI, 1.43 to 5.04) and 4.18 (CI, 2.12 to 8.26), respectively. This risk was most striking among those aged 60 years or younger and men. Increased risk for death associated with Black or Latino race/ethnicity or other sociodemographic characteristics was not detected.Deaths occurring outside

2020 Annals of Internal Medicine

18. Layperson-Led vs Professional-Led Behavioral Interventions for Weight Loss in Pediatric Obesity: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Department of Haematology and Medical Oncology, CancerCare Manitoba, Winnipeg, Canada. 9 Department of Internal Medicine, University of Manitoba, Winnipeg, Canada. PMID: 32658289 PMCID: DOI: Item in Clipboard Full-text links Cite Abstract Importance: The appropriate approach for weight loss among children and adolescents with overweight and obesity remains unclear. Objective: To evaluate the difference in the treatment outcomes associated with behavioral weight loss interventions led by laypersons (...) and professionals in comparison with unsupervised control arms among children and adolescents with overweight and obesity. Data sources: For this systematic review and meta-analysis, the Medical Literature Analysis and Retrieval System Online (MEDLINE), Embase, the Cochrane Library, and Cumulative Index of Nursing and Allied Health Literature (CINAHL) databases were searched from January 1, 1996, to June 1, 2019. Study selection: Included in this study were randomized clinical trials (RCTs) of behavioral

2020 EvidenceUpdates

19. Interventions for the management of obesity in people with bipolar disorder. (Abstract)

in bipolar disorder. Approximately 68% of treatment seeking bipolar patients are overweight or obese. Clinicians are aware that obesity has the potential to contribute to other physical health conditions in people with bipolar disorder, including diabetes, hypertension, metabolic syndrome, cardiovascular disease, and coronary heart disease. Cardiovascular disease is the leading cause of premature death in bipolar disorder, happening a decade or more earlier than in the general population. Contributing (...) Interventions for the management of obesity in people with bipolar disorder. Bipolar disorder is one of the most common serious mental illnesses, affecting approximately 60 million people worldwide. Characterised by extreme alterations in mood, cognition, and behaviour, bipolar disorder can have a significant negative impact on the functioning and quality of life of the affected individual. Compared with the general population, the prevalence of comorbid obesity is significantly higher

2020 Cochrane

20. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jun 3;e200420. doi: 10.1001/jamasurg.2020.0420. Online ahead of print. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial , , , , , , , , , , , , , , , , , , Affiliations Expand

2020 EvidenceUpdates